Medication-Assisted Treatment (MAT)

What is Medication-Assisted Treatment?

Medication-Assisted Treatment is the use of FDA-approved medications, combined with counseling and behavioral therapies, to treat substance use disorders. MAT is the clinically recognized, evidence-based approach for opioid use disorder and an effective option for alcohol use disorder. It treats addiction as the chronic, brain-based condition it is, addressing both the biological pull of addiction and the psychological, behavioral, and social factors that sustain it.

The National Institute on Drug Abuse, SAMHSA, and the American Society of Addiction Medicine all identify MAT as the standard of care for opioid use disorder, citing research showing that medication combined with behavioral therapy reduces illicit drug use, lowers overdose mortality, decreases criminal activity, and improves treatment retention and social functioning. These are not incremental improvements: studies show buprenorphine and methadone reduce opioid overdose deaths by 50 percent or more when access and adherence are sustained.

MAT is not a replacement for counseling and it is not a shortcut around recovery work. Medication stabilizes the brain's chemistry and quiets the cravings and withdrawal symptoms that make it nearly impossible for many people to engage meaningfully in therapy. Once stabilized, clients can apply their full cognitive and emotional capacity to the behavioral work of building a different life. Neither piece produces the same outcome alone.

Medications for opioid use disorder

Buprenorphine is a partial opioid agonist that activates opioid receptors at a fraction of the intensity of heroin or prescription opioids. It reduces cravings, prevents withdrawal, and has a ceiling effect that limits the risk of overdose even at high doses. Buprenorphine is available in several formulations: sublingual films or tablets (Suboxone contains both buprenorphine and naloxone, which deters misuse), monthly injectable Sublocade, and implantable Probuphine. The injectable and implantable options improve adherence for clients who find daily dosing difficult.

Naltrexone (Vivitrol, in its monthly injectable form) is a full opioid antagonist that blocks opioid receptors entirely, preventing any euphoric effect from opioid use. It carries no abuse potential and requires no DEA prescribing waiver. Because it does not produce any opioid effect, naltrexone is often considered for clients who are motivated to avoid any opioid-active medication, or for those in professions with strict substance policies. Naltrexone requires a period of complete opioid abstinence before initiation to avoid precipitating withdrawal.

Methadone for opioid use disorder is a full opioid agonist available through federally certified Opioid Treatment Programs (OTPs). Because of the specialized dispensing requirements, The Archangel Centers refers clients who need methadone to trusted OTP partners rather than prescribing it in the outpatient setting.

• Buprenorphine/naloxone (Suboxone): daily sublingual film or tablet, partial opioid agonist
• Buprenorphine injectable (Sublocade): monthly subcutaneous injection for improved adherence
• Naltrexone (Vivitrol): monthly intramuscular injection, full opioid antagonist, no abuse potential
• Methadone: referred to certified OTP partners; not dispensed in outpatient office setting

Medications for alcohol use disorder

Naltrexone is also the most extensively studied medication for alcohol use disorder. It works by blocking the opioid receptors that mediate the rewarding effects of alcohol, reducing the craving and the pleasurable effect that follow a drink. Trials show naltrexone reduces heavy drinking days, increases abstinence, and improves long-term outcomes when combined with counseling. It is available in daily oral form or as the monthly Vivitrol injection.

Acamprosate (Campral) reduces the anxiety, restlessness, and dysphoria of early alcohol abstinence by stabilizing the glutamate and GABA neurotransmitter systems that alcohol disrupts. It is taken three times daily and is most effective for clients who have already achieved abstinence and are trying to maintain it. Acamprosate is cleared by the kidneys rather than the liver, making it an option for clients with hepatic concerns.

Disulfiram (Antabuse) works differently: it causes an unpleasant physiological reaction when alcohol is consumed by blocking aldehyde dehydrogenase, the enzyme that metabolizes acetaldehyde. It is a deterrence medication that creates a pharmacological barrier to drinking. Its effectiveness depends on adherence, making it most useful when dosing is supervised by a family member or clinical staff.

• Naltrexone (oral or Vivitrol injection): reduces craving and reward of alcohol
• Acamprosate (Campral): reduces abstinence-related anxiety and dysphoria
• Disulfiram (Antabuse): creates aversive reaction to alcohol, deterrence approach

Common myths about MAT

MAT is replacing one addiction with another. This is the most persistent misconception in addiction treatment. The medications used in MAT do not produce the cycle of intoxication, euphoria, and withdrawal that defines addiction. Buprenorphine taken as prescribed produces stability without intoxication. Naltrexone blocks opioid receptors entirely. These are medical treatments for a medical condition, prescribed and monitored by qualified providers. The analogy to insulin in diabetes is imperfect but directionally accurate: using medication to manage a chronic condition is not addiction.

MAT means you are not really in recovery. This claim has no basis in the clinical literature and reflects a cultural rather than scientific standard. SAMHSA, ASAM, and the Betty Ford Institute Consensus Panel define recovery as a process of change through which individuals improve their health and wellness, live self-directed lives, and strive to reach their full potential. Medication that supports that process is consistent with recovery by every authoritative definition.

MAT is only for people who cannot get clean any other way. Clients choose MAT based on clinical evidence and their own treatment goals, not as a last resort. For opioid use disorder in particular, the evidence for MAT is so strong that clinicians are now guided to offer it first rather than withhold it until other approaches have failed.

How MAT decisions are made at The Archangel Centers

MAT decisions are made through a comprehensive clinical assessment that evaluates the severity and history of the substance use disorder, co-occurring medical and mental health conditions, previous treatment experiences, medication preferences, and the client's goals for recovery. The ASAM Criteria provide the framework for placement and treatment planning. No client is placed on MAT without a thorough assessment, and no client who is clinically appropriate is denied access to it based on stigma or assumption.

The prescribing provider, individual therapist, and group clinician coordinate care under one treatment plan. Medication management appointments are integrated into the outpatient schedule rather than handled separately, so the team has a clear picture of how medication is affecting the client's participation in behavioral treatment and vice versa. This coordination is one of the clinical advantages of integrated outpatient care over receiving medication from one provider and counseling from another without a shared plan.

How long does MAT last?

The length of MAT is individualized and is never determined by an arbitrary program timeline or external pressure to discontinue medication quickly. Clinical guidelines from SAMHSA and ASAM support long-term maintenance for opioid use disorder because the evidence shows that premature discontinuation significantly increases relapse risk and overdose mortality. For many clients, buprenorphine or naltrexone is prescribed for a year or more. Some clients benefit from indefinite maintenance.

The decision to taper or discontinue a MAT medication is made collaboratively between the client and prescribing provider based on clinical progress, stability in recovery, the client's own goals, and a careful assessment of risk. A client who has built a strong recovery support structure, maintains stable employment and housing, and has consistent participation in aftercare activities may be an appropriate candidate for a slow, medically supervised taper. A client with recent instability, limited support, or high environmental stress is not a candidate for rapid discontinuation regardless of how long they have been on medication.

MAT and outpatient levels of care at The Archangel Centers

The Archangel Centers provides outpatient care only and does not offer medically supervised detox or inpatient stabilization. When a client requires detox before beginning or continuing MAT, we coordinate that care with trusted medical partners and begin or continue the outpatient program once the client is appropriately stable.

Once in outpatient care, MAT is integrated across all levels. In partial hospitalization, medication management appointments are scheduled within the program week alongside individual therapy, group work, and psychiatric services. As clients step down to IOP and then OP, medication monitoring continues with the same prescribing provider so there are no gaps in clinical oversight during transitions. Both the Tinton Falls, New Jersey and Charlotte, North Carolina programs offer MAT coordination within the outpatient treatment framework.

Insurance coverage for MAT

The Mental Health Parity and Addiction Equity Act (MHPAEA) and the Affordable Care Act require most private insurance plans to cover substance use disorder treatment, including MAT, at parity with coverage for medical and surgical conditions. In practice this means most major commercial insurance plans, including Aetna, Cigna, BlueCross BlueShield, United Healthcare, and Humana, cover MAT-related services when clinically appropriate.

Coverage for specific medications varies by plan and formulary. Buprenorphine products, naltrexone, and acamprosate are typically covered under pharmacy benefits with prior authorization requirements in many plans. The clinical team at The Archangel Centers works with clients to verify coverage, navigate prior authorization, and identify financial assistance options when coverage gaps exist. No client should delay or avoid MAT because of uncertainty about cost.